金城医药：子公司金城金素注射用头孢美唑钠通过仿制药一致性评价

Group 1 - The core point of the article is that Jincheng Pharmaceutical (300233) announced that its subsidiary, Jincheng Jinsu, received approval from the National Medical Products Administration for a supplemental application for injectable Cefmetazole Sodium in various specifications [1] - The approved specifications include 0.25g, 1.0g, and 2.0g, and the drug approval number has been issued with a validity period of 18 months [1] - According to the data from Minet, the sales revenue of injectable Cefmetazole Sodium in domestic public medical institutions is projected to be 1.337 billion RMB, 1.277 billion RMB, and 1.334 billion RMB for the years 2022, 2023, and 2024 respectively [1]